NCT05169177 Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy
| NCT ID | NCT05169177 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Sydney |
| Condition | Liver Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2022-10-17 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2022-10-17 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational study will investigate the properties of image files standardly collected during radiation therapy treatment in a cross-section of liver cancer patients who received stereotactic ablative body radiation therapy (SABR) after trans-catheter arterial chemo emobilisation (TACE). Specifically, it will determine whether the radio-opaque contrast agents in the image files can be detected by tumour-tracking software (KIM).
Eligibility Criteria
Inclusion Criteria: * Received or will receive stereotactic ablative body radiotherapy (SABR) treatment for liver cancer at a participating site. * Received a radio-opaque contrast agent (e.g. Lipiodol™ or DC Bead LUMI™) that is visible on the radiation treatment planning CT scan * The radio-opaque contrast agent mass is or will be within the x-ray imaging field of view during the CBCT scan and any planned intra-fraction imaging. Note that there is no requirement of the distance between the contrast agent mass and the treated tumour as the goal of the study is the contrast agent mass tracking. * Provides written informed consent (prospectively recruited) or meets criteria for waiving of the requirement for consent (retrospectively recruited) Exclusion Criteria: * Less than 18 years of age * Minimum image dataset is not available * Image dataset is not in a compatible format
Contact & Investigator
Paul Keall, PhD
STUDY CHAIR
University of Sydney
Frequently Asked Questions
Who can join the NCT05169177 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Liver Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05169177 currently recruiting?
Yes, NCT05169177 is actively recruiting participants. Contact the research team at Shona.Silvester@sydney.edu.au for enrollment information.
Where is the NCT05169177 trial being conducted?
This trial is being conducted at Waratah, Australia, Westmead, Australia, Woolloongabba, Australia, Melbourne, Australia and 1 additional location.
Who is sponsoring the NCT05169177 clinical trial?
NCT05169177 is sponsored by University of Sydney. The principal investigator is Paul Keall, PhD at University of Sydney. The trial plans to enroll 50 participants.